Since the 1950s, a large number of tumor immunology studies have proved that the body has a specific immune response to tumor, which has opened up a new way for tumor treatment. Immunotherapy has become one of the important means of tumor treatment. Experimental and clinical studies have shown that the immune cells of the body can clear tumors. After surgical resection of the primary tumor, immunotherapy should be used to kill the residual tumor cells and eliminate the factors of recurrence and metastasis. Next redbert (Beijing) Biotechnology Co., Ltd. will take us to understand the development and current situation of tumor immunotherapy.

In April 2010, FDA approved a therapeutic vaccine for advanced prostate cancer and metastatic prostate cancer. Many authoritative journals commented that the approval of prostate cancer vaccine is an epoch-making event. The emergence of cancer immunotherapy and the approval of cancer vaccine have opened the gate for the future.

1、 Current status of tumor immunotherapy

1. Although it is not widely recognized as traditional surgery, radiotherapy and chemotherapy, with the confirmation of some small clinical studies, more and more doctors and patients accept this method with little toxic and side effects and most likely to cure tumors.

2. The basic and clinical research of tumor immunotherapy is the fastest developing field in oncology academic conferences at home and abroad.

3. At the end of 2012, the famous American journal Science listed "tumor immunotherapy" as one of the most noteworthy fields in the six major scientific fields in 2013.

2、 Challenges of tumor immunotherapy

1. The complexity of tumor biological characteristics, immune response and tumor tolerance;

2. Lack of clear biological criteria to evaluate the clinical efficacy of tumor immunotherapy;

3. Animal models are difficult to predict the efficacy of tumor immunotherapy;

4. Few drugs can be combined with immunotherapy.

5. The traditional clinical response standard does not consider the difference between toxic drugs and immunotherapy;

6. The funds for tumor immunotherapy transformation research and clinical trial are limited;

7. Long waiting time for approval of clinical trials of tumor immunotherapy;

8. Standardization, standardization and personalization of cell products for tumor immune cell therapy.

3、 Difficulties in tumor immunotherapy

1. Tumor immunotherapy has been seriously ignored in clinical practice

Immunity is not only the basis of cancer prevention, but also a part of cancer treatment.

2. The immune function of tumor patients has complex tolerance problems

The whole immune system; Local tumor; T. B, NK, regulatory cells, tumor associated macrophages, etc; Suppression of immune activation and excessive immune tolerance.

3. There are also many problems in the field of tumor immunotherapy

Cell quality and preparation technology; Immune mechanism; Excessive pursuit of economic interests; Lack of immune knowledge.

4. The theory of tumor immunotherapy is backward, and the technology is lack of traditional theory update, doctor knowledge update and technical innovation.

It is believed that with the in-depth study of tumor immunotherapy, it will develop rapidly in the future. At present, beacon has a single-cell photoconductive system. By integrating photoelectric positioning technology and microfluidic technology, it realizes the high-throughput cell biology research based on single cells in the nano upgrade chamber of the chip, which is of great significance in the research of tumor immunotherapy. Beacon can operate 14000 or 7000 single cells per batch, ensure the high yield of cell lines, easily realize 99.5% monoclonal, fundamentally reduce the cost, and has full image recording and perfect report, which can provide strong evidence for subsequent applications. It has automatic operation and variant design, which can greatly reduce the manual operation and system error of traditional equipment conversion, with high accuracy and high cost performance.

* The above contents are collected online for reference only. If this site article involves copyright and other issues, please contact this site in time, and we will deal with it as soon as possible!